GB0812649D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0812649D0
GB0812649D0 GBGB0812649.2A GB0812649A GB0812649D0 GB 0812649 D0 GB0812649 D0 GB 0812649D0 GB 0812649 A GB0812649 A GB 0812649A GB 0812649 D0 GB0812649 D0 GB 0812649D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0812649.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Priority to GBGB0812649.2A priority Critical patent/GB0812649D0/en
Publication of GB0812649D0 publication Critical patent/GB0812649D0/en
Priority to EP09785309A priority patent/EP2321305A1/en
Priority to CN2009801269686A priority patent/CN102089298A/en
Priority to JP2011517249A priority patent/JP2011527335A/en
Priority to US13/003,573 priority patent/US20110178054A1/en
Priority to PCT/GB2009/050831 priority patent/WO2010004348A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0812649.2A 2008-07-10 2008-07-10 Compounds Ceased GB0812649D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0812649.2A GB0812649D0 (en) 2008-07-10 2008-07-10 Compounds
EP09785309A EP2321305A1 (en) 2008-07-10 2009-07-10 Heterocyclic gpcr agonists
CN2009801269686A CN102089298A (en) 2008-07-10 2009-07-10 Heterocyclic gpcr agonists
JP2011517249A JP2011527335A (en) 2008-07-10 2009-07-10 Heterocyclic GPCR agonist
US13/003,573 US20110178054A1 (en) 2008-07-10 2009-07-10 Heterocyclic GPCR Agonists
PCT/GB2009/050831 WO2010004348A1 (en) 2008-07-10 2009-07-10 Heterocyclic gpcr agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0812649.2A GB0812649D0 (en) 2008-07-10 2008-07-10 Compounds

Publications (1)

Publication Number Publication Date
GB0812649D0 true GB0812649D0 (en) 2008-08-20

Family

ID=39722074

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0812649.2A Ceased GB0812649D0 (en) 2008-07-10 2008-07-10 Compounds

Country Status (6)

Country Link
US (1) US20110178054A1 (en)
EP (1) EP2321305A1 (en)
JP (1) JP2011527335A (en)
CN (1) CN102089298A (en)
GB (1) GB0812649D0 (en)
WO (1) WO2010004348A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207155B2 (en) 2009-03-31 2012-06-26 Vanderbilt University Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders
JP2012530758A (en) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel compounds, pharmaceutical compositions and methods relating thereto
TW201111361A (en) 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (en) 2010-11-18 2013-04-10 Prosidion Ltd DERIVATIVES OF DISPOSED 1,4-PIRROLIDINS AND 3-IL-AMINAS AND THEIR USES IN THE TREATMENT OF METABOLIC DISORDERS
JP5935154B2 (en) * 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング N-cyclopropyl-N-piperidinylbenzamide as a GPR119 modulator
CA2831334A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
JP6094578B2 (en) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted piperidines as GPR119 modulators for the treatment of metabolic disorders
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
US9006228B2 (en) 2011-06-16 2015-04-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
AU2012339870B2 (en) 2011-11-15 2017-06-29 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
AU2013240183B2 (en) 2012-03-26 2016-10-20 Axcella Health Inc. Charged nutritive proteins and methods
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN107223020A (en) 2013-09-25 2017-09-29 胺细拉健康公司 Composition and preparation and its generation and the method that controls for glucose and calorie for preventing and treating diabetes and obesity
WO2018068295A1 (en) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
EP0934941A1 (en) * 1996-08-09 1999-08-11 Eisai Co., Ltd. Benzopiperidine derivatives
US5834261A (en) * 1997-05-27 1998-11-10 Biocatalytics, Inc. Method for the production of chiral vicinal aminoalcohols
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
US20100063081A1 (en) * 2005-06-30 2010-03-11 Stuart Edward Bradly CPCR Agonists
CN101511429A (en) * 2006-07-13 2009-08-19 史密丝克莱恩比彻姆公司 Indulines derivatives and gpr119 agonists
JP2010514828A (en) * 2007-01-04 2010-05-06 プロシディオン・リミテッド Piperidine GPCR agonist
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081659A1 (en) * 2007-01-04 2008-10-24 Prosidion Ltd GPCR AGONISTS
EP2114936A1 (en) * 2007-01-04 2009-11-11 Prosidion Limited Piperidine gpcr agonists
PE20081849A1 (en) * 2007-01-04 2009-01-26 Prosidion Ltd PIPERIDIN-4-IL-PROPOXY-BENZAMIDE DERIVATIVES AS GPCR AGONISTS

Also Published As

Publication number Publication date
CN102089298A (en) 2011-06-08
EP2321305A1 (en) 2011-05-18
JP2011527335A (en) 2011-10-27
WO2010004348A1 (en) 2010-01-14
US20110178054A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
GB0807862D0 (en) Compounds
GB0800035D0 (en) Compounds
GB0812649D0 (en) Compounds
GB0812641D0 (en) Compounds
GB0809776D0 (en) Compounds
GB0807103D0 (en) Compounds
GB0800367D0 (en) Compounds
GB0807910D0 (en) Compounds
GB0801220D0 (en) Compounds
GB0801265D0 (en) Compounds
GB0811029D0 (en) Compounds
GB0809771D0 (en) Compounds
GB0800455D0 (en) Compounds
GB0800961D0 (en) Compounds
GB0800338D0 (en) Compounds
GB0801219D0 (en) Compounds
GB0802231D0 (en) Compounds
GB0802586D0 (en) Compounds
GB0816960D0 (en) Compounds
GB0807911D0 (en) Compounds
GB0812622D0 (en) Compounds
GB0811450D0 (en) Compounds
GB0811449D0 (en) Compounds
GB0811203D0 (en) Compounds
GB0804064D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)